Search Results - "Jadidi‐Niaragh, F."

Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis by Jadidi‐Niaragh, F., Mirshafiey, A.

“…Multiple sclerosis (MS) is an autoimmune disease characterized by recurrent episodes of demyelination and axonal lesion mediated by CD4+ T cells with a…”
Get full text

Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency by Azizi, G., Kiaee, F., Hedayat, E., Yazdani, R., Dolatshahi, E., Alinia, T., Sharifi, L., Mohammadi, H., Kavosi, H., Jadidi‐Niaragh, F., Ziaee, V., Abolhassani, H., Aghamohammadi, A.

“…Common variable immunodeficiency (CVID) is the most prevalent symptomatic type of human primary immunodeficiency diseases (PID). Clinically, CVID is…”
Get full text

The Role of Natural Killer Cells in Alzheimer's Disease by Jadidi-Niaragh, F., Shegarfi, H., Naddafi, F., Mirshafiey, A.

“…Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive dysfunction and selective neuronal death in the brain. The…”
Get full text

CTLA-4 Expression in CD4+ T Cells From Patients With LRBA Deficiency and Common Variable Immunodeficiency With No Known Monogenic Disease by Azizi, G, Jamee, M, Yazdani, R, Bagheri, Y, Fayyaz, F, Jadidi-Niaragh, F, Abolhassani, H, Aghamohammadi, A

Get full text

The profile of IL-4, IL-5, IL-10 and GATA3 in patients with LRBA deficiency and CVID with no known monogenic disease: Association with disease severity by Azizi, G, Bagheri, Y, Yazdani, R, Zaki-Dizaji, M, Jamee, M, Jadidi-Niaragh, F, Kamali, A N, Abolhassani, H, Aghamohammadi, A

“…Common variable immunodeficiency (CVID) is the most common symptomatic form of primary immunodeficiency (PID). LPS-responsive beige-like anchor protein (LRBA)…”
Get more information

Nanoparticles and targeted drug delivery in cancer therapy by Bahrami, Behdokht, Hojjat-Farsangi, Mohammad, Mohammadi, Hamed, Anvari, Enayat, Ghalamfarsa, Ghasem, Yousefi, Mehdi, Jadidi-Niaragh, Farhad

“…•Nanomedicine improved the current immunotherapeutic approaches.•Nanomaterials can reduce the adverse effects of current anti-cancer drugs.•Targeted drug…”
Get full text

The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer by Masjedi, Ali, Hashemi, Vida, Hojjat-Farsangi, Mohammad, Ghalamfarsa, Ghasem, Azizi, Gholamreza, Yousefi, Mehdi, Jadidi-Niaragh, Farhad

“…•IL-6 and its associated signaling promote cancer progression.•Targeting IL-6 signaling axis can arrest tumor growth.•Blockage of IL-6 and IL-6R can be…”
Get full text

CD73 as a potential opportunity for cancer immunotherapy by Ghalamfarsa, Ghasem, Kazemi, Mohammad Hossein, Raoofi Mohseni, Sahar, Masjedi, Ali, Hojjat-Farsangi, Mohammad, Azizi, Gholamreza, Yousefi, Mehdi, Jadidi-Niaragh, Farhad

“…Cancer cells apply various mechanisms to induce and enhance immune escape. The complex network of immune-response modulating factors in the tumor…”
Get more information

Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer by Kazemi, Mohammad H., Raoofi Mohseni, Sahar, Hojjat‐Farsangi, Mohammad, Anvari, Enayat, Ghalamfarsa, Ghasem, Mohammadi, Hamed, Jadidi‐Niaragh, Farhad

“…Tumor cells overcome anti‐tumor responses in part through immunosuppressive mechanisms. There are several immune modulatory mechanisms. Among them, adenosine…”
Get full text

Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer by Karpisheh, Vahid, Nikkhoo, Afshin, Hojjat-Farsangi, Mohammad, Namdar, Afshin, Azizi, Gholamreza, Ghalamfarsa, Ghasem, Sabz, Gholamabas, Yousefi, Mehdi, Yousefi, Bahman, Jadidi-Niaragh, Farhad

“…•Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages.•Prostanoids and particularly prostaglandin E2…”
Get full text

The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia by Eghbal‐Fard, Shadi, Yousefi, Mehdi, Heydarlou, Hanieh, Ahmadi, Majid, Taghavi, Simin, Movasaghpour, Aliakbar, Jadidi‐Niaragh, Farhad, Yousefi, Bahman, Dolati, Sanam, Hojjat‐Farsangi, Mohammad, Rikhtegar, Reza, Nouri, Mohammad, Aghebati‐Maleki, Leili

“…Problem Inappropriate activation of the immune system, particularly the imbalance of T‐helper type 17 (Th17)/regulatory T (Treg) cells is thought to play…”
Get full text

CDK1 in Breast Cancer: Implications for Theranostic Potential by Izadi, Sepideh, Nikkhoo, Afshin, Hojjat-Farsangi, Mohammad, Namdar, Afshin, Azizi, Gholamreza, Mohammadi, Hamed, Yousefi, Mehdi, Jadidi-Niaragh, Farhad

“…Breast cancer has been identified as one of the main cancer-related deaths among women during some last decades. Recent advances in the introduction of novel…”
Get more information

Oncostatin M: A mysterious cytokine in cancers by Masjedi, Ali, Hajizadeh, Farnaz, Beigi Dargani, Farzaneh, Beyzai, Behzad, Aksoun, Mohsen, Hojjat-Farsangi, Mohammad, Zekiy, Angelina, Jadidi-Niaragh, Farhad

“…•OSM is a tumor site dominant cytokine associated with the immunopathogenesis of numerous cancers.•STAT3 acts as the main transcription factor in the OSM…”
Get full text

Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine by Hassannia, Hadi, Ghasemi Chaleshtari, Mitra, Atyabi, Fatemeh, Nosouhian, Mahshid, Masjedi, Ali, Hojjat‐Farsangi, Mohammad, Namdar, Afshin, Azizi, Gholamreza, Mohammadi, Hamed, Ghalamfarsa, Ghasem, Sabz, Gholamabas, Hasanzadeh, Sajad, Yousefi, Mehdi, Jadidi‐Niaragh, Farhad

“…Summary Dendritic cell (DC) ‐based cancer immunotherapy is one of the most important anti‐cancer immunotherapies, and has been associated with variable…”
Get full text

Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review by Jamee, Mahnaz, Moniri, Shakiba, Zaki-Dizaji, Majid, Olbrich, Peter, Yazdani, Reza, Jadidi-Niaragh, Farhad, Aghamahdi, Fatemeh, Abolhassani, Hassan, Condliffe, Alison M., Aghamohammadi, Asghar, Azizi, Gholamreza

“…Activated phosphoinositide 3-kinase delta syndrome (APDS) is a novel primary immunodeficiency (PID) caused by heterozygous gain of function mutations in PI3Kδ…”
Get full text

Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway by Masjedi, Ali, Hassannia, Hadi, Atyabi, Fatemeh, Rastegari, Ali, Hojjat-Farsangi, Mohammad, Namdar, Afshin, Soleimanpour, Hassan, Azizi, Gholamreza, Nikkhoo, Afshin, Ghalamfarsa, Ghasem, Mirshafiey, Abbas, Jadidi-Niaragh, Farhad

“…Adenosine and its receptors are novel promising targets for cancer immunotherapy. In here, we aimed to evaluate the efficacy of Polyethylene glycol…”
Get full text

PD-L1/PD-1 axis as a potent therapeutic target in breast cancer by Bastaki, Shima, Irandoust, Mahzad, Ahmadi, Armin, Hojjat-Farsangi, Mohammad, Ambrose, Patrick, Hallaj, Shahin, Edalati, Mahdi, Ghalamfarsa, Ghasem, Azizi, Gholamreza, Yousefi, Mehdi, Chalajour, Hengameh, Jadidi-Niaragh, Farhad

“…Although both the incidence and the mortality rate of breast cancer is rising, there is no potent and practical option for the treatment of these patients,…”
Get full text

The prognostic and therapeutic potential of vimentin in colorectal cancer by Kalaei, Zahra, Shekarchi, Ali Akbar, Hojjat-Farsangi, Mohammad, Jalali, Pooya, Jadidi-Niaragh, Farhad

“…Several cells and molecules in the tumor microenvironment have been introduced as effective factors in the prognosis and progression of colorectal cancer. As a…”
Get full text

Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression by Masjedi, Ali, Ahmadi, Armin, Atyabi, Fatemeh, Farhadi, Shohreh, Irandoust, Mahzad, Khazaei-Poul, Yalda, Ghasemi Chaleshtari, Mitra, Edalati Fathabad, Mahdi, Baghaei, Masoumeh, Haghnavaz, Navideh, Baradaran, Behzad, Hojjat-Farsangi, Mohammad, Ghalamfarsa, Ghasem, Sabz, Gholamabas, Hasanzadeh, Sajad, Jadidi-Niaragh, Farhad

“…The immunosuppressive nature of the tumor microenvironment is a critical problem that should be considered before the design of immunotherapies. Interleukin…”
Get full text

Mechanisms of tumor cell resistance to the current targeted-therapy agents by Khamisipour, Gholamreza, Jadidi-Niaragh, Farhad, Jahromi, Abdolreza Sotoodeh, zandi, Keivan, Hojjat-Farsangi, Mohammad

“…Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug…”
Get full text